Lucatumumab
Based on 1 Customer Validation
Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: ≥99.0%
- No. CAS: 903512-50-5
- Peso molecular:144.5 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas TNF Receptor
More
Actividad biológica
Human IgG1 kappa
Human
|
CD40 |
Lucatumumab (0.001-10 μg/mL; 4 h; 37 °C) inhibit B-cell chronic lymphocytic leukemia (B-CLL) growth by ADCC-mediated cell lysis, with the average maximal lysis of B-CLL cells of 49%[1].
Lucatumumab (0.1-10 μg/mL; 3 d) inhibits CD40L-induced signaling and viability of B-CLL cells[1].
Lucatumumab (10 μg/mL; 24 h) inhibits cytokine secretion by B-CLL cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:B-cell chronic lymphocytic leukemia (B-CLL)
-
Concentration:0.001 to 10 μg/mL
-
Incubation Time:72 hours; 37 ℃
-
Result:Inhibited B-CLL growth with an ED50 of 14 pM and a average maximal lysis of B-CLL cells of 49%.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized CD40 Protein, Human (HEK293, His, HY-P73499A) can bind Lucatumumab. The EC50 for this effect is 4.606 ng/mL. -
Flow Cytometry analysis of Raji cells labelling TNFRSF5/CD40 (red) with Lucatumumab (anti-TNFRSF5/CD40) (HY-P99167). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
No. CAS 903512-50-5
-
Appearance Liquid
-
Peso molecular 144.5 kDa
-
Color Colorless to light yellow
-
SMILES
[Lucatumumab]
-
Synonyms
HCD122
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (259 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
[1]. Luqman M, et al. The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood. 2008 Aug 1;112(3):711-20. [Content Brief]
[2]. Drgona L, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S83-S94. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Lucatumumab Related Classifications
HY-P99167 Related Classifications
Powered by Bioz